Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today held its Annual Meeting of Shareholders in a virtual-only format. Preliminary results from the Annual Meeting indicate that all four proposals were approved by Vaxart shareholders.

Shareholders voted on all proposals in alignment with the Company's recommendations from the 2023 Proxy Statement:

• Election of six director nominees
• Ratification of WithumSmith+Brown, PC as Vaxart’s independent registered public accounting firm
• Approval of “say-on-pay”
• Approval of once every year on “say-on-frequency”

"We appreciate the continued support of our shareholders," said Andrei Floroiu, Chief Executive Officer. "Your votes and confidence in our team enables us to advance our transformative oral pill vaccine program that carries potential of bringing game changing solutions to significant public health challenges worldwide.”

The final results are subject to verification by the independent inspectors of election. The final results will be reported on a Current Report on Form 8-K to be filed by Vaxart with the U.S. Securities and Exchange Commission in the next few days.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.